Literature DB >> 35505029

Investigation of the Therapeutic Potential of Nanobody-Targeted Photodynamic Therapy in an Orthotopic Head and Neck Cancer Model.

Pieter B A A van Driel1, Stijn Keereweer2, Clemens W G M Lowik3, Sabrina Oliveira4,5.   

Abstract

Photodynamic therapy (PDT) has a great therapeutic potential because it induces local cellular cytotoxicity upon application of a laser light that excites a photosensitizer, leading to toxic reactive oxygen species. Nevertheless, PDT still is underutilized in the clinic, mostly because of damage induced to normal surrounding tissues. Efforts have been made to improve the specificity. Nanobody-targeted PDT is one of such approaches, in which the variable domain of heavy-chain antibodies, i.e., nanobodies, are used to target photosensitizers selectively to cancer cells. In vitro studies are certainly very valuable to evaluate the therapeutic potential of PDT approaches, but many aspects such as bio-distribution of the photosensitizers, penetration through tissues, and clearance are not taken into account. In vivo studies are therefore essential to assess the influence of such factors, in order to gain more insights into the therapeutic potential of a treatment under development. This chapter describes the development of an orthotopic model of head and neck cancer, to which nanobody-targeted PDT is applied, and the therapeutic potential is assessed by immunohistochemistry one day after PDT.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Head and neck cancer; Nanobody; Preclinical model; Targeted photodynamic therapy; Therapeutic potential

Mesh:

Substances:

Year:  2022        PMID: 35505029     DOI: 10.1007/978-1-0716-2099-1_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis.

Authors:  Stijn Keereweer; Jeroen D F Kerrebijn; Isabel M Mol; J Sven D Mieog; Pieter B A A Van Driel; Robert J Baatenburg de Jong; Alexander L Vahrmeijer; Clemens W G M Löwik
Journal:  Head Neck       Date:  2011-10-10       Impact factor: 3.147

2.  Nanobody-photosensitizer conjugates for targeted photodynamic therapy.

Authors:  Raimond Heukers; Paul M P van Bergen en Henegouwen; Sabrina Oliveira
Journal:  Nanomedicine       Date:  2014-01-03       Impact factor: 5.307

3.  Detection of oral squamous cell carcinoma and cervical lymph node metastasis using activatable near-infrared fluorescence agents.

Authors:  Stijn Keereweer; J Sven D Mieog; Isabel M Mol; Pieter B A A Van Driel; Thomas J A Snoeks; Robert J Baatenburg de Jong; Alexander L Vahrmeijer; Jeroen D F Kerrebijn; Clemens W G M Löwik
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-06

4.  Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody.

Authors:  P B A A van Driel; J R van der Vorst; F P R Verbeek; S Oliveira; T J A Snoeks; S Keereweer; B Chan; M C Boonstra; J V Frangioni; P M P van Bergen en Henegouwen; A L Vahrmeijer; C W G M Lowik
Journal:  Int J Cancer       Date:  2013-12-12       Impact factor: 7.396

5.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

6.  Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models.

Authors:  Lindsay S Moore; Esther de Boer; Jason M Warram; Matthew D Tucker; William R Carroll; Melissa L Korb; Margaret S Brandwein-Gensler; Gooitzen M van Dam; Eben L Rosenthal
Journal:  Cancer Med       Date:  2016-05-11       Impact factor: 4.452

7.  Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.

Authors:  Timo W M De Groof; Vida Mashayekhi; Tian Shu Fan; Nick D Bergkamp; Javier Sastre Toraño; Jeffrey R van Senten; Raimond Heukers; Martine J Smit; Sabrina Oliveira
Journal:  Mol Pharm       Date:  2019-06-19       Impact factor: 4.939

8.  EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.

Authors:  Pieter B A A van Driel; Martin C Boonstra; Maxime D Slooter; Raimond Heukers; Marieke A Stammes; Thomas J A Snoeks; Henriette S de Bruijn; Paul J van Diest; Alexander L Vahrmeijer; Paul M P van Bergen En Henegouwen; Cornelis J H van de Velde; Clemens W G M Löwik; Dominic J Robinson; Sabrina Oliveira
Journal:  J Control Release       Date:  2016-03-15       Impact factor: 9.776

9.  Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging.

Authors:  Henriette S de Bruijn; Vida Mashayekhi; Tom J L Schreurs; Pieter B A A van Driel; Gustav J Strijkers; Paul J van Diest; Clemens W G M Lowik; Ann L B Seynhaeve; Timo L M Ten Hagen; Jeanine J Prompers; Paul M P van Bergen En Henegouwen; Dominic J Robinson; Sabrina Oliveira
Journal:  Theranostics       Date:  2020-01-20       Impact factor: 11.556

10.  Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.

Authors:  Marion M Deken; Marta M Kijanka; Irati Beltrán Hernández; Maxime D Slooter; Henriette S de Bruijn; Paul J van Diest; Paul M P van Bergen En Henegouwen; Clemens W G M Lowik; Dominic J Robinson; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  J Control Release       Date:  2020-04-21       Impact factor: 9.776

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.